摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,5-Ditert-butyl-1,3,4-oxadiazole

中文名称
——
中文别名
——
英文名称
2,5-Ditert-butyl-1,3,4-oxadiazole
英文别名
——
2,5-Ditert-butyl-1,3,4-oxadiazole化学式
CAS
——
化学式
C10H18N2O
mdl
——
分子量
182.26
InChiKey
WAMGWOYNRRZVBL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    38.9
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • Hepatitis C Virus Inhibitors
    申请人:Bristol-Myers Squibb Company
    公开号:US20130183269A1
    公开(公告)日:2013-07-18
    The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    本公开涉及抗病毒化合物,更具体地涉及能够抑制丙型肝炎病毒(HCV)编码的NS5A蛋白功能的化合物组合,包括这种组合的组成物,以及抑制NS5A蛋白功能的方法。
  • HEPATITIS B ANTIVIRAL AGENTS
    申请人:ENANTA PHARMACEUTICALS, INC.
    公开号:US20160289212A1
    公开(公告)日:2016-10-06
    The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R 1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    本发明公开了化合物的结构式(I),或其药学上可接受的盐、酯或前药: X-A-Y-Z-L-R 1 (I) 这些化合物抑制由乙型肝炎病毒(HBV)编码的蛋白质或干扰乙型肝炎病毒的生命周期功能,并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物,用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
  • Selective androgen receptor modulators
    申请人:Miller Chris P.
    公开号:US20090253758A1
    公开(公告)日:2009-10-08
    This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, and or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, and intermediates useful in the preparation of same.
    本发明提供了公式I、Ia、Ib、Ic、Id、Ie的化合物,以及它们的盐,包含这些化合物的药物组合物和药用辅料,调节雄激素受体方法,治疗可受益于雄激素受体调节剂(例如,肌肉减少症、前列腺癌、避孕、2型糖尿病相关疾病或病症、贫血、抑郁和肾脏疾病)的疾病的方法,以及制造公式I、Ia、Ib、Ic、Id、Ie的化合物和用于制备这些化合物的中间体的过程。
  • NITROGEN-CONTAINING HETEROARYL DERIVATIVES
    申请人:Bleicher Konrad
    公开号:US20110183979A1
    公开(公告)日:2011-07-28
    The invention is concerned with novel nitrogen-containing heteroaryl derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.
    本发明涉及式(I)的新氮杂芳基衍生物,其中R1、R2、R3、R4、R5、A1、A2和Y的定义如描述和权利要求中所述,以及这些化合物的生理可接受的盐和酯。这些化合物可以抑制PDE10A,并可作为药物使用。
  • HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION
    申请人:BARTOLOZZI Alessandra
    公开号:US20130196967A1
    公开(公告)日:2013-08-01
    The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R 1 -R 7 , A and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    本发明涉及式(I)的化合物: 或其药用可接受的盐,其中R1-R7、A和HET按本文定义。本发明还涉及包含这些化合物的药物组合物,使用这些化合物治疗各种疾病和失调的方法,以及制备这些化合物和在这些过程中有用的中间体的方法。
查看更多